Aktuellt
SENASTE
Redeye revisits its view of Herantis in the wake of the company’s shifted strategy toward HER-096– an engineered derivative of its previous lead drug CDNF that allows for non-invasive administration. We slightly raise our base case to SEK 24 per share (22) and expect Herantis to take the important step back into the clinic now in H1 2023.
LÄS MER
